China's regime 'feels threatened internally' says expert
We use your sign-up to provide content in ways you’ve consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info
Silence Therapeutics PLC has teamed up Hansoh Pharma in a deal that could be worth $1.3billion (£1billion) in milestone payments.
The UK gene silencing specialist will receive an “upfront” $16million (£11million) as part of the collaboration.
The two aim to create new treatments using Silence’s mRNAi GOLD platform, which has been specially created to find liver disease treatments.
MORE TO FOLLOW
Source: Read Full Article